At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 48 enrolled
Drug / intervention
rLP2086 vaccine or control +3 morebiological
Likely dose
rLP2086 vaccine or control 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Randomized, Open-label, Parallel-group, Active- And Placebo-controlled Study To Assess Safety And Tolerability Of 60, 120, And 200 Mcg Meningococcal Group B Rlp2086 Vaccine In Healthy Adult Subjects
In Brief
A Phase 1 clinical trial evaluating rLP2086 vaccine or control for Meningitis, Meningococcal. Completed, enrolled 48 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the safety and tolerability of an investigational meningococcal B rLP2086 vaccine in healthy adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMeningitis, Meningococcal
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2009
First PostedApr 2009
Primary CompletionJul 2012
TodayJul 2026
First PostedApr 13, 2009
Enrollment StartApr 1, 2009
Primary CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 17.2 years ago
Interventions
rLP2086 vaccine or controlbiological
intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
rLP2086 vaccine or controlbiological
intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
rLP2086 vaccine or controlbiological
intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
rLP2086 vaccine or controlbiological
intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months